New Ventures III

New Ventures III operates as an early-stage venture capital fund, established in 2023, specializing in the nascent phases of healthcare and biotechnology innovation. Co-managed by Scientia Ventures and Redesign Health, the fund provides strategic capital and operational expertise to cultivate companies developing solutions across computational biology, digital health, and artificial intelligence applications within medicine. Its approach emphasizes active partnership to translate scientific breakthroughs into market-ready enterprises.

The fund's inception in 2023 leverages the distinct philosophies of its co-managers. Scientia Ventures, led by individuals such as Harry Glorikian, evolved from New Ventures Funds with a focus on the convergence of life sciences, data, and technology. Concurrently, Redesign Health, founded by CEO Brett Shaheen in 2018, entered the market with an insight into the fragmented nature of healthcare innovation, aiming to build companies from conception to scale. Their combined expertise forms the bedrock of New Ventures III.

New Ventures III serves a dual constituency: the limited partners seeking exposure to high-growth healthcare ventures and the early-stage companies themselves, which benefit from tailored support and industry access. The fund's vision is to systematically address significant challenges within the healthcare ecosystem by identifying and nurturing transformative technologies. It aims to accelerate the development of the next generation of healthcare leaders, fostering a healthier future through strategic investment and hands-on guidance.